Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
| العنوان: | Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes |
|---|---|
| المؤلفون: | Paul Strumph, Julio Rosenstock, Bruce W. Bode, Arthur T. Sands, Pablo Lapuerta, Phillip Banks, John B. Buse, Rubina A. Heptulla, Satish K. Garg, Brian Zambrowicz, Marc Rendell, William T. Cefalu |
| المصدر: | Diabetes Care |
| بيانات النشر: | American Diabetes Association, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Hypoglycemia, Placebo, Young Adult, Double-Blind Method, Glucosides, Weight loss, Internal medicine, Diabetes mellitus, Weight Loss, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Insulin, Glycosides, Benzhydryl Compounds, Glycemic, Advanced and Specialized Nursing, Type 1 diabetes, Dose-Response Relationship, Drug, business.industry, urogenital system, Middle Aged, medicine.disease, Combined Modality Therapy, Endocrinology, Diabetes Mellitus, Type 1, Treatment Outcome, Diabetes Care Symposium, Drug Therapy, Combination, Female, SGLT2 Inhibitor, medicine.symptom, business |
| الوصف: | OBJECTIVE To assess the safety and efficacy of dual sodium–glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes. RESEARCH DESIGN AND METHODS We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, or placebo in a randomized, double-blind trial assessing safety, insulin dose, glycemic control, and other metabolic parameters over 29 days of treatment. RESULTS In the sotagliflozin-treated group, the percent reduction from baseline in the primary end point of bolus insulin dose was 32.1% (P = 0.007), accompanied by lower mean daily glucose measured by continuous glucose monitoring (CGM) of 148.8 mg/dL (8.3 mmol/L) (P = 0.010) and a reduction of 0.55% (5.9 mmol/mol) (P = 0.002) in HbA1c compared with the placebo group that showed 6.4% reduction in bolus insulin dose, a mean daily glucose of 170.3 mg/dL (9.5 mmol/L), and a decrease of 0.06% (0.65 mmol/mol) in HbA1c. The percentage of time in target glucose range 70–180 mg/dL (3.9–10.0 mmol/L) increased from baseline with sotagliflozin compared with placebo, to 68.2% vs. 54.0% (P = 0.003), while the percentage of time in hyperglycemic range >180 mg/dL (10.0 mmol/L) decreased from baseline, to 25.0% vs. 40.2% (P = 0.002), for sotagliflozin and placebo, respectively. Body weight decreased (1.7 kg) with sotagliflozin compared with a 0.5 kg gain (P = 0.005) in the placebo group. CONCLUSIONS As adjunct to insulin, dual SGLT1 and SGLT2 inhibition with sotagliflozin improved glycemic control and the CGM profile with bolus insulin dose reduction, weight loss, and no increased hypoglycemia in type 1 diabetes. |
| اللغة: | English |
| تدمد: | 1935-5548 0149-5992 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c955470f1e98e74071c86429dc8be8e9Test http://europepmc.org/articles/PMC4831906Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c955470f1e98e74071c86429dc8be8e9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19355548 01495992 |
|---|